Table 1.

Critical trials of bevacizumab for metastatic colorectal cancer

Basic chemotherapy	Clinic trial (references)	Bevacizumab schedule	Median PFS	Median OS
Irinotecan
IFL	AVF21073	5 mg/kg IV, every 2 weeks	10.6 vs 6.2 months, P < 0.001	20.3 vs 15.6 months, P < 0.001
FOLFIRI or mIFL	BICC-C24,25,a	FOLFIRI+Bev: 5 mg/kg IV, every 2 weeks; mIFL+Bev: 7.5 mg/kg IV, every 3 weeks	7.6 vs 5.9 months	23.1 vs 17.6 months (without Bev); 28.0 vs 19.2 months (with Bev)
Oxaliplatin
FOLFOX or XELOX	NO1696626,b	7.5 mg/kg IV, every 3 weeks	9.4 vs 8.0 months, P = 0.0023	21.3 vs 19.9 months; P = 0.077
FOLFOX4	E320027	10 mg/kg IV, every 14 days	7.2 vs 4.8 months; P < 0.0001	12.5 vs 10.7 months; P = 0.0024
FOLFOX or bFOL or CAPOX	TREE-1 and TREE-2 (with Bev)15,b	FOLFOX and bFOL: 5 mg/kg IV, every 2 weeks; CapeOx: 7.5 mg/kg IV, every 3 weeks	8.7, 6.9, and 5.9 vs 9.9, 8.3, and 10.3 months	19.2, 17.9, and 17.2 vs 26.1, 20.4, and 24.6 months
5-FU
5-FU/LV	AVF0780, AVF2107 and AVF219228,29,d	5 mg/kg IV, every 2 weeks	8.8 vs 5.6 months, P ≤ 0.001	17.9 vs 14.6 months, P = 0.008

Notes:

^aPrimary aim was to compare FOLFIRI with mIFL;

^bThe “on treatment” PFS benefit is larger;

^cThey are two independent trials, without comparison directly;

^dIt’s a combined analysis of the three trials.

Abbreviations: IV, intravenous; Bev, bevacizumab; mIFL, modified IFL.